Medicus Pharma reduces Teverelix royalty rate to 2%, simplifies structure.
ByAinvest
Thursday, Jan 22, 2026 7:35 am ET1min read
MDCX--
• Medicus Pharma reduces Teverelix royalty structure from 4% to 2% • Simplifies royalty structure while preserving global rights and IP control • Teverelix is a potential market product for Acute Urinary Retention Relapse prevention (AURr) and prostate cancer • Potential market opportunity is around US$6 billion • Medicus Pharma is a precision guided biotech/life sciences company focused on advancing therapeutics assets.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet